奥美拉唑肠溶片与多潘立酮片联合治疗喉咽反流性疾病的疗效观察

Observation on Efficacy of Omeprazole Combined with Domperidone in Treatment of Laryngopharyngeal Reflux Disease

目的:探讨奥美拉唑肠溶片与多潘立酮片联合治疗喉咽反流性疾病的疗效。方法:选取营口市中心医院2014年2月—2015年2月收治的喉咽反流性疾病患者110例,按随机数字表法分为2组各55例。对照组患者给予奥美拉唑肠溶片进行治疗,观察组患者在对照组治疗基础上联合多潘立酮片进行治疗,治疗结束后,对2组患者的疗效、唾液胃蛋白酶1、3、4周转阴率以及不良反应发生情况进行比较。结果:观察组患者总有效率为94.55%(52/55),对照组为69.09%(38/55),2组的差异有统计学意义(P<0.05);观察组患者唾液胃蛋白酶转阴率1周为43例(78.18%)、3周50例(90.91%)、4周51例(92.73%),与对照组的28例(50.91%)、42例(76.36%)、43例(78.18%)比较,2组的差异有统计学意义(P<0.05);观察组患者发生不良反应5例(9.09%),对照组4例(7.27%),2组的差异无统计学意义(P<0.05)。结论:奥美拉唑肠溶片与多潘立酮片联合治疗喉咽反流性疾病效果显著,且无严重不良反应,值得临床推广。

OBJECTIVE：To probe into the efficacy of omeprazole combined with domperidone in treatment of laryngopharyngeal reflux disease.METHODS：110 patients with hypopharynx reflux disease admitted into Yingkou Central Hospital from Feb.2014 to Feb.2015 were selected to be divided into two groups via the random number table,with 55 cases in each.The control group were treated with omeprazole,while the observation group additionally received domperidone on the basis of control group.After treatment,the efficacy,saliva pepsin negative rate in the1 st,3rd and 4ed week and incidence of adverse reactions were compared between two group of patients.RESULTS：The total efficacy of observation group was 94.55%（52 /55）,and control group was 69.09%（38 /55）,with statistically significant difference（P 〈0.05）.In observation group,the saliva pepsin negative rate in the 1st week was78.18%（43 cases）,in the 3rd week was 90.91%（50 cases） and in the 4ed week was 92.73%（51 cases）,compared with the data in control group [50.91%（28 cases）,76.36%（42 cases） and 78.18%（43 cases） ],the difference was statistically significant（P 〈0.05）.There were 5 cases（9.09%） of adverse reactions in observation group,and 4 cases（7.27%） in control group,with statistical significance（P〈 0.05）.CONCLUSIONS：The efficacy of omeprazole combined with domperidone in treatment of laryngopharyngeal reflux disease is remarkable,without any severe adverse reactions,which is worthy of clinical promotion and application.